(Total Views: 258)
Posted On: 04/06/2022 11:30:32 AM
Post# of 1418
Re: whytestocks #758
This is great news on so many levels for Todos, investors and consumers
1.) Increases consumer's success whether taking it daily or acute which I like that wording. The risk before was you had people taking Tollovid daily with an acute regime. It was worked, great, but wasn't intended for that so if it didn't, then you'd have complaints or something worse.
2.) Simplifies things for consumers. Now you have the best product on the field that can be taken daily or one you have acute symptoms. One bottle to by and 1 or 2 use cases if you need
3.) Simplifies Todos manufacturing and supply chain. 1 Skew instead of 2 cuts cost.
4.) Simplifies Marketing
5.) Increases margins significantly
6.) Accelerates OTC path
7.) Hope for Long Covid sufferers
8.) PR is very White House friendly
Probably missed a few, but investors get the point
1.) Increases consumer's success whether taking it daily or acute which I like that wording. The risk before was you had people taking Tollovid daily with an acute regime. It was worked, great, but wasn't intended for that so if it didn't, then you'd have complaints or something worse.
2.) Simplifies things for consumers. Now you have the best product on the field that can be taken daily or one you have acute symptoms. One bottle to by and 1 or 2 use cases if you need
3.) Simplifies Todos manufacturing and supply chain. 1 Skew instead of 2 cuts cost.
4.) Simplifies Marketing
5.) Increases margins significantly
6.) Accelerates OTC path
7.) Hope for Long Covid sufferers
8.) PR is very White House friendly
Probably missed a few, but investors get the point
(0)
(0)
